Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Unicycive Therapeutics (UNCY) Other Non Operating Income (2021 - 2024)

Unicycive Therapeutics posted quarterly Other Non Operating Income of -$11.8 million for Q1 2024, down 13.36% year-on-year from -$13.6 million in Q2 2023, and down 13.36% on a QoQ basis from -$10.4 million in Q1 2023.

Unicycive Therapeutics (UNCY) has 3 years of Other Non Operating Income data on file, last reported at -$11.8 million in Q1 2024.

  • For the quarter ending Q1 2024, Other Non Operating Income fell 13.36% year-over-year to -$11.8 million; the trailing twelve-month figure through Mar 2024 stood at -$22.1 million (down 113.36% YoY), and the FY2023 full-year result was -$9.8 million, down 162733.33% from the prior year.
  • Other Non Operating Income for Q1 2024 stood at -$11.8 million, down from -$10.4 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $19000.0 in Q1 2021 and bottomed at -$11.8 million in Q1 2024.
  • The 3-year median for Other Non Operating Income is -$10.4 million (2023), against an average of -$7.4 million.
  • Peak annual rise in Other Non Operating Income reached 13.36% in 2024, while the deepest fall reached 13.36% in 2024.
  • A 3-year view of Other Non Operating Income shows it stood at $19000.0 in 2021, then tumbled by 54694.74% to -$10.4 million in 2023, then dropped by 13.36% to -$11.8 million in 2024.
  • The last three Other Non Operating Income figures came in at -$11.8 million (Q1 2024), -$10.4 million (Q1 2023), and $19000.0 (Q1 2021), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Unicycive Therapeutics 181.94 Mn 127.36 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2024 -11.76 Mn
Mar 31, 2023 -10.37 Mn
Mar 31, 2021 19,000.00